| Literature DB >> 32999368 |
Udomluk Leungtongkam1, Rapee Thummeepak1, Thawatchai Kitti2, Kannipa Tasanapak1, Jintana Wongwigkarn1, Kathryn M Styles3, Elizabeth M H Wellington3, Andrew D Millard4, Antonia P Sagona3, Sutthirat Sitthisak5.
Abstract
In this study, we examined the association between antimicrobial resistance, CRISPR/Cas systems and virulence with phage susceptibility in Acinetobacter baumannii and investigated draft genomes of phage susceptible multidrug resistant A. baumannii strains from Thailand. We investigated 230 A. baumannii strains using 17 lytic A. baumannii phages and the phage susceptibility was 46.5% (107/230). Phage susceptibility was also associated with resistance to numerous antibiotics (p-value < 0.05). We also found association between biofilm formation and the presence of ompA gene among phage susceptible A. baumannii strains (p-value < 0.05). A. baumannii isolates carrying cas5 or combinations of two or three other cas genes, showed a significant increase in phage resistance. Whole-genome sequences of seven phage susceptible A. baumannii isolates revealed that six groups of antibiotic resistance genes were carried by all seven phage susceptible A. baumannii. All strains carried biofilm associated genes and two strains harbored complete prophages, acquired copper tolerance genes, and CRISPR-associated (cas) genes. In conclusion, our data exhibits an association between virulence determinants and biofilm formation among phage susceptible A. baumannii strains. These data help to understand the bacterial co-evolution with phages.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32999368 PMCID: PMC7528101 DOI: 10.1038/s41598-020-73123-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
List of bacteriophages used in this study.
| Previous bacteriophage nomenclature | Bacteriophages (full name; abbreviated name) | Source of isolate | References | |
|---|---|---|---|---|
| ØABP-01; PAB01 | vB_AbaP_PhT01; vPhT01 | Waste water HE | A1589a | Kitti[ |
| ØABP-02; PAB02 | vB_AbaM_PhT02; vPhT02 | Waste water HE | A1389a, AB183b | Kitti[ |
| ØABP-04; PAB04 | vB_AbaM_PhT04; vPhT04 | Waste water HE | A1522a, AB22b | Kitti[ |
| ØABP-05; PAB05 | vB_AbaX_PhT05; vPhT05 | Waste water HE | A1521a | Kitti[ |
| ØABP-09; PAB09 | vB_AbaX_PhT09; vPhT09 | Waste water HE | A1589a, AB20b | Kitti[ |
| ØABP-19; PAB19 | vB_AbaP_PhT19; vPhT19 | Waste water HE | A1589a | Kitti[ |
| ØABP-25; PAB25 | vB_AbaX_PhT25; vPhT25 | Waste water HE | A1589a | Kitti[ |
| ØABP-29; PAB29 | vB_AbaP_PhT29; vPhT29 | Waste water HG | A1589a, AB20b | Kitti[ |
| ØABP-35; PAB35 | vB_AbaX_PhT35; vPhT35 | Waste water HG | A1589a | Kitti[ |
| ØABP-38; PAB38 | vB_AbaX_PhT38; vPhT38 | Waste water HE | A1589a | Kitti[ |
| ØABP-39; PAB39 | vB_AbaP_PhT39; vPhT39 | Waste water HE | A1511a, AB22b | Kitti[ |
| ØABP-40; PAB40 | vB_AbaX_PhT40; vPhT40 | Waste water HE | A1522a | Kitti[ |
| ØABP-44; PAB44 | vB_AbaM_PhT44; vPhT44 | Waste water HE | ATCC19606a, AB20b | Kitti[ |
| ØABP-48; PAB48 | vB_AbaX_PhT48; vPhT48 | Waste water HG | A1522a | Kitti[ |
| ØABP-49; PAB49 | vB_AbaX_PhT49; vPhT49 | Waste water HG | A1521a | Kitti[ |
| ØABP-52; PAB52 | vB_AbaX_PhT52; vPhT52 | Waste water HG | A1522a | Kitti[ |
| ØABP-55; PAB55 | vB_AbaX_PhT55; vPhT55 | Waste water HG | A1589a | Kitti[ |
All phages were isolated in 2010 from Buddhachinaraj hospital (HE) and Bang Rakam hospital (HG), Phitsanulok, Thailand.
aHost strains for phage isolation.
bHost strains for phage propagation.
Figure 1UPGMA dendrogram based on phage susceptibility patterns among 230 A. baumannii clinical isolates.) Tree branches represent three bacterial groups of phage susceptibility (Group1: green, Group2 red, Group 3 blue), phage susceptible is displayed as yes (black) and no (gray). Hospitals A-E located in Central, Lower Northern, Northern, East and Northern regions of Thailand, respectively. Hospital F, located in Nepal. Classifications of MDR-, CR-, XDR- and non MDR-AB were presented as yes (black) and no (gray). Antibiotic sensitivity is presented as resistant (green) and susceptible (gray). Antibiotics are abbreviated as follows: AK amikacin, CIP ciprofloxacin, SXT trimethoprim/sulfamethoxazole, CTX cefotaxime, CAZ ceftazidime, CSL cefoperazone/sulbactam, IPM imipenem, MEM meropenem, PIP piperacillin/tazobactam, TE tetracycline, CRO ceftriaxone, FEP cefepime, CN gentamicin.
Association between antibiotics, drug resistance patterns and phage susceptibility.
| Antibiotics/drug resistance patterns | No. of phage susceptible isolates | ||
|---|---|---|---|
| Drug resistant | Drug susceptible | ||
| Amikacin (AK) | 80/123 (65.04%) | 27/107 (25.23%) | |
| Ciprofloxacin (CIP) | 104/196 (53.06%) | 3/34 (8.82%) | |
| Trimethoprim/sulfamethoxazole (SXT) | 75/151 (49.67%) | 32/79 (40.51%) | 0.1859 |
| Cefotaxime (CTX) | 96/185 (51.89%) | 11/45 (24.44%) | |
| Ceftazidime (CAZ) | 100/191 (52.35%) | 7/39 (17.95%) | |
| Cefoperazone/sulbactam (CSL) | 38/66 (57.57%) | 69/164 (42.07%) | |
| Imipenem (IPM) | 103/189 (54.49%) | 4/41 (9.76%) | |
| Meropenem (MEM) | 104/188 (55.32%) | 3/42 (7.14%) | |
| Piperacillin/tazobactam (PIP) | 101/190 (53.16%) | 6/40 (15.00%) | |
| Tetracycline (TE) | 89/142 (62.67%) | 18/88 (20.45%) | |
| Ceftriaxone (CRO) | 101/193(52.33%) | 6/37 (16.22%) | |
| Cefepime (FEP) | 89/170 (52.35%) | 18/60 (30.00%) | |
| Gentamicin (CN) | 83/146 (56.85%) | 24/84 (28.57%) | |
| MDR-AB | 105/199 (52.76%) | 2/31 (6.45%) | |
| CR-AB | 103/192 (53.64%) | 4/38 (10.53%) | |
| XDR-AB | 20/28 (71.43%) | 87/202 (43.07%) | |
| Non MDR-AB | 2/28 (7.14%) | 105/202 (51.98%) | |
*p-values less than 0.05 were considered as a statistically significant difference (Fisher's exact test). Bold font indicates statistically significant difference between two groups.
Association between biofilm formation, ompA gene and copper tolerance among phage susceptible A. baumannii strains.
| Biofilm formation and copper tolerance | No. of phage susceptible isolates | ||
|---|---|---|---|
| Positive (Yes) | Negative (No) | ||
| Biofilm formation phenotype | 88/173 (50.87%) | 19/57 (33.33%) | |
| 101/198 (51.01%) | 6/32 (18.75%) | ||
| Copper tolerance phenotype | 9/53 (16.98%) | 98/177 (55.37%) | |
| 9/46 (19.56%) | 98/184 (53.26%) | ||
*p-values less than 0.05 were considered as a statistically significant difference (Fisher's exact test) and are shown in bold.
Comparisons of CRISPR-associated (cas) genes between phage susceptible and resistant A. baumannii.
| Characteristics | No. of isolates | ||
|---|---|---|---|
| Phage susceptible | Phage resistant | ||
| 11/107 (10.28%) | 21/123 (17.07%) | 0.1376 | |
| 0/107 (0.00%) | 2/123 (1.67%) | NC | |
| 9/107 (8.41%) | 21/123 (17.07%) | 0.0517 | |
| 8/107 (7.47%) | 26/123 (21.14%) | ||
| 2/107 (1.87%) | 5/123 (4.06%) | NC | |
| 0/107 (0.00%) | 0/123 (0.00%) | NC | |
| Positive for two or three | 9/107 (8.41%) | 23/123 (18.70%) | |
Bold font indicates statistically significant difference between two groups.
NC not comparable.
*p-values less than 0.05 were considered as statistically significant difference (Fisher's exact test).
Figure 2Whole-genome SNP-based phylogenetic tree. A phylogenetic tree base on WGS analysis showing the relationship between seven phage susceptible A. baumannii and 149 published A. baumannii genomes. Colours indicate four major clusters (A = green, B = purple, C = red, and D = blue). Seven phage susceptible A. baumannii strains are marked with dots.
Genome features, acquired antimicrobial resistance genes, putative prophages, copper tolerance, virulence genes, and CRISPR-associated (cas) genes identified in whole genome sequences of phage susceptible A. baumannii.
| Strain ID/Genome characteristics | AB003 | AB053 | AB089 | AB135 | AB140 | AB229 | AB329 |
|---|---|---|---|---|---|---|---|
| Hospital/year isolated | HE/2006 | HA/2013 | HA/2013 | HB/2014 | HB/2014 | HB/2014 | HD/2015 |
| Specimens | Sputum | Sputum | Sputum | Pus | Sputum | Urine | Sputum |
| Phage susceptibility | (9/17) | (2/17) | (3/17) | (3/17) | (4/17) | (3/17) | (6/17) |
| Number of assembled contigs | 57 | 142 | 174 | 99 | 77 | 333 | 256 |
| Average genome size (bp) | 4,050,570 | 4,108,360 | 3,897,375 | 4,036,789 | 3,990,813 | 4,070,648 | 3,943,615 |
| GC content (%) | 38.8 | 38.9 | 39.0 | 38.9 | 39.8 | 39.1 | 39.0 |
| Number of CDSs | 3,965 | 4,059 | 3,808 | 3,955 | 3,875 | 4,134 | 3,923 |
| Number of RNAs | 70 | 69 | 70 | 72 | 73 | 68 | 68 |
| MLST/Rep type | ST1/R34 | ST129/R15 | ST2/R4 | ST2/R4 | ST2/R4 | ST2/R4 | ST98/R4 |
| Sulfonamide resistance | ND | ND | |||||
| Tetracycline resistance | ND | ||||||
| Beta-lactam resistance | |||||||
| Aminoglycoside resistance | |||||||
| Macrolide resistance | ND | ||||||
| Phenicol resistance | ND | ND | ND | ND | ND | ND | |
| Iron acquisition | |||||||
| Biofilm formation | |||||||
| Type V, VI and IV secretion systems | |||||||
| Other systems | |||||||
| Copper tolerance (genotype/phenotype) | |||||||
| Number of prophages (complete/incomplete) | 9 (1/8) | 8 (1/7) | 4 (0/4) | 10 (0/10) | 5 (0/5) | 8 (0/8) | 6 (0/6) |
| Plasmid replicon typing (GR) | GR2, GR6 | GR1, GR2, pRAY | GR2 | GR2, GR6 | GR2, GR6 | GR2, GR6 | GR2 |
| CRISPR-associated ( | CAS-TypeI ( | Negative | Negative | Negative | Negative | Negative | CAS-TypeI ( |
| Accession no/Bioproject | PRJEB32181 | JABCNM000000000 | JABCNJ000000000 | JABCNK000000000 | JABCNI000000000 | JABCNL000000000 | JABCNH000000000 |
| Reference | Thummeepak et al.[ | This study | This study | This study | This study | This study | This study |
ND not detected.